Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | EYA2 | O00167 | 1/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.64 |
| ▸ | ACE | P12821 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Edetic Acid SCHEMBL8371874 | 0.98 | TDP1 (0.61) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL5073273 | 0.92 | TDP1 (0.54) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL21113636 | 0.89 | TDP1 (0.50) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL6284520 | 0.89 | TDP1 (0.50) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL476467 | 0.86 | TDP1 (0.52) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL6142172 | 0.86 | TDP1 (0.47) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL138172 | 0.81 | TDP1 (0.56) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL1976384 | 0.80 | TDP1 (0.88) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL16714076 | 0.80 | TDP1 (1.00) | TDP1EYA2APPACEBLM | |
| Edetic Acid SCHEMBL8607480 | 0.80 | TDP1 (1.00) | TDP1EYA2APPACEBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 310 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11337989-B2 | Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound | EVOFEM, INC. (US) | 2022-05-24 | — | — | US | claimed |
| EP-3735966-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION AND DISEASES USING AN ALGINIC ACID-BASED ANTIMICROBIAL COMPOUND | Evofem, Inc. (US) | 2020-11-11 | — | — | EP | claimed |
| EP-3128992-B1 | ORAL CARE COMPOSITIONS | BASF SE (DE) | 2019-11-20 | — | — | EP | claimed |
| EP-3308771-A1 | COMPOSITIONS AND METHODS FOR ENHANCING THE EFFICACY OF CONTRACEPTIVE MICROBICIDES | Evofem, Inc. (US) | 2018-04-18 | — | — | EP | claimed |
| WO-2015070072-A1 | METHODS FOR MANUFACTURING CONTRACEPTIVE MICROBICIDES WITH ANTIVIRAL PROPERTIES | EVOFEM, INC. (US) | 2015-05-14 | — | — | WO | claimed |
| WO-2009043588-A2 | PH REGULATING ANTIBACTERIAL FILMS FOR THE ORAL OR VAGINAL CAVITY | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH (DE) | 2009-04-09 | — | — | WO | claimed |
| US-20240199648-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-06-20 | — | — | US | disclosed |
| EP-4380613-A1 | HIV-1 VACCINATION AND SAMT-247 MICROBICIDE TO PREVENT HIV-1 INFECTION | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2024-06-12 | — | — | EP | disclosed |
| US-11992472-B2 | Compositions and methods for enhancing the efficacy of contraceptive microbicides | EVOFEM, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| EP-3455224-B1 | SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRIDINE-3(2H)-ONES AND 2,5,6,7-TETRAHYDRO-3H-PYRROLO[2,1-C][1,2,4]TRIAZOL-3-ONES, AND USE THEREOF | BAYER AG (DE) | 2024-03-27 | — | — | EP | disclosed |
| EP-4305041-A1 | MAP4K1 INHIBITORS | Blueprint Medicines Corporation (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023220645-A1 | VACCINE FOR HUMAN T-LYMPHOTROPIC VIRUS-1 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4244910-A1 | CERIUM-ETHYLENEDIAMINE KETONE-TYPE AND CERIUM-SALEN-TYPE COMPLEXES AND USE THEREOF IN ORGANIC ELECTRONICS | Credoxys GmbH c/o Institut for Applied Physics (DE) | 2023-09-20 | — | — | EP | disclosed |
| EP-0168342-A1 | Process for the preparation of thrombin inhibitors | CIBA-GEIGY AG (CH) | 1986-01-15 | — | — | EP | disclosed |
| EP-0160552-A2 | Contrast agents for NMR imaging | VESTAR, INC. (US) | 1985-11-06 | — | — | EP | disclosed |
| EP-0146785-A1 | Process for the preparation of protease inhibitors | CIBA-GEIGY AG (CH) | 1985-07-03 | — | — | EP | disclosed |
| EP-0139843-A2 | Liquid magnesium-containing formulations | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-05-08 | — | — | EP | disclosed |
| EP-0136973-A1 | Method and composition for disinfecting water | Strausak, Benedikt (CH) | 1985-04-10 | — | — | EP | disclosed |
| US-4469631-A | GENETIC ENGINEERING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1984-09-04 | — | — | US | disclosed |
| US-4350764-A | GENETIC ENGINEERING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1982-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199648-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | TDP1 756/4885EYA2 397/4885APP 1117/4885 |
| US-11337989-B2 | Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound | ALG8, ALG1, EIF2AK2 | TDP1 3637/4885EYA2 3705/4885APP 3516/4885 |
| US-11992472-B2 | Compositions and methods for enhancing the efficacy of contraceptive microbicides | PGF, PGRMC1, PGRMC2 | TDP1 1933/4885EYA2 3238/4885APP 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.